# Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

> **NCT07456852** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 60 (estimated)

## Conditions studied

- Malignant Digestive System Neoplasm

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Capecitabine
- **DRUG:** Diltiazem Hydrochloride
- **PROCEDURE:** Electrocardiogram
- **DRUG:** Fluorouracil
- **DEVICE:** Holter Monitoring
- **DRUG:** Isosorbide Mononitrate
- **OTHER:** Medical Device Usage and Evaluation
- **DRUG:** Placebo Administration
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT07456852
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2028-03-31
- **Final completion:** 2030-03-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07456852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07456852, "Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT07456852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*